Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Renal Impairment | Zendy

Luning Zhuang | Zendy; Kunyi Wu | Zendy; Seong H. Jang | Zendy; Kellie S. Reynolds | Zendy; Shrimant Mishra | Zendy; Dmitri Iarikov | Zendy

Open Access

Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Renal Impairment

Author(s) -

Luning Zhuang,

Kunyi Wu,

Seong H. Jang,

Kellie S. Reynolds,

Shrimant Mishra,

Dmitri Iarikov

Publication year - 2022

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02074-21

Subject(s) - medicine , regimen , nephrotoxicity , therapeutic drug monitoring , population , pharmacokinetics , incidence (geometry) , urology , intensive care medicine , pharmacology , kidney , physics , environmental health , optics

In 2018, the FDA approved plazomicin for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in adult patients with limited or no alternative treatment options. The objective of this article is to provide the scientific rationales behind the recommended dosage regimen and therapeutic drug monitoring (TDM) of plazomicin in cUTI patients with renal impairment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research